1) Financial Performance Overview
- IDEXX reported a 14% increase in revenue for Q1 2026, with 11% organic growth driven by strong performance in the companion animal business. - CAG Diagnostics recurring revenues grew 11% organically, with 12% growth internationally and nearly 11% in the U.S.. - Operating profit increased by 15%, leading to an EPS of $3.47, reflecting a 15% growth on a comparable basis. - The company raised its full-year revenue guidance to between $4.675 billion and $4.76 billion, indicating an overall growth of 8.6% to 10.6%.

2) Segment Performance Insights
- CAG Diagnostics recurring revenue growth was impacted by a 1% decline in U.S. same-store clinical visits, particularly in wellness visits, which fell 3%. - Strong instrument placements resulted in a 28% organic growth in CAG instrument revenues, with 1,100 IDEXX inVue Dx analyzers placed during the quarter. - Global Reference Lab revenues increased 10% organically, supported by significant volume growth and new customer acquisitions. - IDEXX VetLab consumables saw a 15% organic growth, driven by strong demand for new testing capabilities.

3) Strategic Initiatives and Innovations
- IDEXX emphasized its commitment to innovation, with successful launches of the inVue Dx platform and Cancer DX, enhancing diagnostic capabilities. - The rollout of F&A (Fine Needle Aspiration) is progressing well, with plans for broader launch later in the year, aiming to improve diagnostic workflows. - The company is focusing on AI advancements within its platforms to enhance diagnostic insights and operational efficiency.

4) Challenges and Market Dynamics
- The company faces headwinds from a decline in wellness visits and macroeconomic pressures affecting consumer spending on discretionary veterinary care. - Supply chain disruptions in the Water business were noted, particularly affecting international growth, but overall demand remains strong. - IDEXX is adjusting its expectations for U.S. clinical visits, now forecasting a decline of 1.5% for the year, reflecting ongoing challenges in the wellness segment.

5) Guidance and Future Outlook
- For Q2 2026, IDEXX anticipates reported revenue growth of 7.3% to 9.3%, with organic growth of 6.7% to 8.7%. - The company expects to maintain its full-year EPS outlook of $14.45 to $14.90, reflecting continued operational performance despite external pressures. - The leadership transition to Mike Erickson is expected to drive further innovation and growth strategies, with a focus on expanding diagnostics and software capabilities.

Bottom line: IDEXX Laboratories is positioned for continued growth in 2026, driven by strong performance in diagnostics and innovative product launches, despite facing challenges in clinical visits and macroeconomic pressures. The company's strategic focus on enhancing customer relationships and expanding its diagnostic capabilities should sustain its competitive advantage and shareholder value.